# Jasper Therapeutics, Inc. (JSPRW) — capital_raise/private_placement [completed]
Source: sec.gov · situation sit_3d66ec8c03cb2682e194 · public 8458279589992898425 · retrieved 2026-08-19T12:08:40.144Z

## Overview
Jasper Therapeutics is a clinical-stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, with a consolidated pipeline including KP-104 (a dual complement inhibitor), briquilimab (an anti-KIT antibody), and KP-701 (a dual-acting anti-CD79BxCD32B monoclonal antibody).

Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals, a Cayman limited company focused on complement therapies for immune-mediated diseases, on July 16, 2026. Concurrently, Jasper closed a private placement of non-voting convertible preferred stock co-led by Affinity Asset Advisors and Ikarian Capital, raising approximately $132 million in gross proceeds from leading life science investors.

## Terms
- Counterparty: Kira Pharmaceuticals · Deal value: $132.0M · Consideration: stock

## Key dates
- Completed 2026-07-16

## Timeline
- 2026-08-14 · 8-K (0001213900-26-090055): 8-K - Jasper Therapeutics, Inc. — *Jasper Therapeutics is a clinical-stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, with a consolidated pipeline including KP-104 (a dual complement inhibitor), briquilimab (an anti-KIT antibody), and KP-701 (a dual-acting anti-CD79BxCD32B monoclonal antibody).* Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals, a Cayman limited company focused on complement therapies for immune-mediated diseases, on July 16, 2026. Concurrently, Jasper closed a private placement of non-voting convertible preferred stock co-led by Affinity Asset Advisors and Ikarian Capital, raising approximately $132 million in gross proceeds from leading life science investors.
  https://www.sec.gov/Archives/edgar/data/1788028/0001213900-26-090055.txt

## Citations
- 0001213900-26-090055 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000121390026090055